Journal
AUTOIMMUNITY REVIEWS
Volume 12, Issue 11, Pages 1085-1090Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2013.05.004
Keywords
Catastrophic antiphospholipid syndrome; Refractory; Rituximab; Anti-CD20
Categories
Ask authors/readers for more resources
The catastrophic variant of the antiphospholipid syndrome (APS) is characterized by thrombosis in multiple organs developing over a short period of time. First-line treatment for the catastrophic APS is the combination of anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulin. Despite this regimen, the mortality remains high and new treatment options are needed. By a systematic review of the Catastrophic APS Registry (CAPS Registry), we identified 20 patients treated with rituximab. The purpose of this study is to describe the clinical manifestations, laboratory features, and outcomes of rituximab-treated CAPS patients. In addition, the rationale for using rituximab in catastrophic APS is discussed. (C) 2013 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available